Zhejiang Agricultural Co., Ltd. (002758): Zhejiang Agricultural Co., Ltd. took the initiative to build an integrated service platform for agricultural materials, automobiles and pharmaceuticals
Huatong Pharmaceutical (002758) In-depth Report: “One aircraft, two wings” is about to take off in the Chinese medicine formula granule policy
Huatong Pharmaceutical (002758) Quarterly report comments: the performance is in the upper limit of the forecast, and the revenue of traditional Chinese medicine formula granules is expected to accelerate significantly from the second quarter.
KuaiBao of Huatong Pharmaceutical (002758) Co., Ltd.: Dingzeng steadily promotes the business of traditional Chinese medicine formula granules is expected to exceed expectations
Comments on Huatong Pharmaceutical (002758) Annual report: the performance of traditional Chinese medicine formula granules is affected in the short term.
Comment on the event of Huatong Pharmaceutical (002758) Co., Ltd.: 16 years' performance is lower than expected. 17 years is the first year of the growth of traditional Chinese medicine formula particles.
Comment on the event of Huatong Pharmaceutical (002758) Company: the non-public offering has been accepted by the Securities Regulatory Commission and the business of traditional Chinese medicine formula granules is progressing smoothly.
[founder Securities] Huatong Pharmaceutical: the non-public offering has been accepted by the CSRC, and the company's traditional Chinese medicine formula granule business is progressing smoothly.
Huatong Pharmaceutical (002758) follow-up report: traditional Chinese medicine formula particles are expected to be fully incorporated into the performance elasticity of health insurance companies in the province.
[founder Securities] Huatong Pharmaceutical: traditional Chinese medicine formula particles are expected to be fully incorporated into health insurance in the province, and the company's performance flexibility has been greatly improved.
华通医药(002758)三季报点评:主业平稳 静待中药配方颗粒放量
【西南证券】华通医药:主业平稳,静待中药配方颗粒放量
华通医药(002758)季报点评:三季报业绩符合预期 四季度开始中药配方颗粒将显著增厚公司业绩
【方正证券】华通医药:三季报业绩符合预期,四季度开始中药配方颗粒将显著增厚公司业绩
华通医药(002758)调研快报:中药饮片和配方颗粒业务循序渐进 商业板块根基扎实
华通医药(002758)跟踪报告:被低估的中药配方颗粒区域龙头企业
【方正证券】华通医药:被低估的中药配方颗粒区域龙头企业
【华泰证券】华通医药:5月27日上市首日定价报告
华通医药(002758):5月27日上市首日定价报告
【恒泰证券】华通医药:预计公司上市初期股价压力位为42元-45元
No Data
No Data